Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL8036967 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL685473 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL192129 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8099424 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL3676 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075366 | 0.99 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148728-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-05-09 | — | — | US | claimed |
| EP-4297788-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | Nanyang Technological University (SG) | 2024-01-03 | — | — | EP | claimed |
| US-20230172933-A1 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-06-08 | — | — | US | claimed |
| WO-2022182292-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | claimed |
| WO-2021188052-A1 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-09-23 | — | — | WO | claimed |
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | claimed |
| US-20180243217-A1 | NANOPARTICLES COMPRISING A STABILIZED BORONIC ACID COMPOUND | LEON-NANODRUGS GMBH (DE) | 2018-08-30 | — | — | US | claimed |
| US-20170360872-A1 | USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 | BIOXCEL CORPORATION (US) | 2017-12-21 | — | — | US | claimed |
| US-20250043014-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4368185-A1 | COMBINATION OF MENIN INHIBITOR(S) AND IMMUNOPROTEASE INHIBITOR(S) FOR TREATMENT OF LEUKEMIA | Universitätsmedizin Greifswald (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-20240148728-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-05-09 | — | — | US | disclosed |
| CN-117820347-A | Method for synthesizing bortezomib by continuous flow | 深圳智微通科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4297788-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | Nanyang Technological University (SG) | 2024-01-03 | — | — | EP | disclosed |
| CN-110799193-B | Copper and nickel catalyzed decarboxylation borylation | 斯克利普斯研究院 | 2023-12-12 | — | — | CN | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20090131367-A1 | Combinations of HDAC Inhibitors and Proteasome Inhibitors | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009036281-A2 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-19 | — | — | WO | disclosed |
| WO-2003077928-A1 | PEPTIDE ANALOGUES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131367-A1 | Combinations of HDAC Inhibitors and Proteasome Inhibitors | HDAC6, HDAC5, HDAC1 | PSMB5 25/4885PSMB8 39/4885PSMB9 52/4885 |
| US-20180243217-A1 | NANOPARTICLES COMPRISING A STABILIZED BORONIC ACID COMPOUND | BCL6, BCL6B, MCL1 | PSMB5 124/4885PSMB8 671/4885PSMB9 175/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PSMB5 3575/4885PSMB8 4568/4885PSMB9 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.